{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:11:09Z","timestamp":1775884269944,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejca.2023.03.041","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T11:25:07Z","timestamp":1680866707000},"page":"99-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Do more targets allow more cancer treatments, or not?"],"prefix":"10.1016","volume":"187","author":[{"given":"Paolo","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9345-2855","authenticated-orcid":false,"given":"Silvia","family":"Calabria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-8961","authenticated-orcid":false,"given":"Carlo","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Botticelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nello","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2023.03.041_bib1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41576-021-00338-8","article-title":"Clinical cancer genomic profiling","volume":"22","author":"Chakravarty","year":"2021","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.ejca.2023.03.041_bib2","doi-asserted-by":"crossref","unstructured":"Yam C., Ma B.B.Y., Yap T.A. Global implementation of precision oncology. JCO Precis Oncol. 2021. May 18;5:PO.21.00001.","DOI":"10.1200\/PO.21.00001"},{"issue":"1","key":"10.1016\/j.ejca.2023.03.041_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.ejca.2023.03.041_bib4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2023.03.041_bib5","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site - when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.03.041_bib6","unstructured":"European Medicine Agency. Keytruda - pembrolizumab. 2022. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/keytruda\u3009."},{"issue":"34","key":"10.1016\/j.ejca.2023.03.041_bib7","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2023.03.041_bib8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Robert C.,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.03.041_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00266","article-title":"Efficacy of vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation: an open-label, single-arm cohort of the histology-independent VE-BASKET study","author":"Subbiah","year":"2019","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.ejca.2023.03.041_bib10","doi-asserted-by":"crossref","unstructured":"Botticelli A., Scagnoli S., Conte P.F., et al., Genomic profiling to expand precision cancer medicine: the ROME trial, in ESMO TAT - Targeted Anticancer Therapies. 2023: 6\u20138 March, Paris.","DOI":"10.1016\/j.esmoop.2023.100928"},{"issue":"5","key":"10.1016\/j.ejca.2023.03.041_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268477","article-title":"Ekinci O. Development and validation of ACTE-MTB: a tool to systematically assess the maturity of molecular tumor boards","volume":"17","author":"Love","year":"2022","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ejca.2023.03.041_bib12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41416-022-01922-3","article-title":"Patient attrition in Molecular Tumour Boards: a systematic review","volume":"127","author":"Frost","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2023.03.041_bib13","article-title":"Clinical outcomes of molecular tumor boards: a systematic review","volume":"5","author":"Larson","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2023.03.041_bib14","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.2217\/fon-2021-0286","article-title":"Popoli P.,et al. Molecular tests and target therapies in oncology: recommendations from the Italian workshop","volume":"17","author":"Pinto","year":"2021","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.03.041_bib15","first-page":"525","article-title":"Vats P.,et al. Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors","volume":"7","author":"Cobain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2023.03.041_bib16","first-page":"190","article-title":"Applicability of ESMO-MCBS and ESCAT for molecular tumor boards. Memo","volume":"15","author":"Wolff","year":"2022","journal-title":"Mag\u00a0Eur\u00a0Med\u00a0Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.03.041_bib17","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Hopman W.M.,et al. Evolution of the randomized clinical trial in the era of precision oncology","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2023.03.041_bib18","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jama.2014.13235","article-title":"Indication-specific pricing for cancer drugs","volume":"312","author":"Bach","year":"2014","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.ejca.2023.03.041_bib19","article-title":"Accelerating patient access to oncology medicines with multiple indications in Europe","volume":"9","author":"Lawlor","year":"2021","journal-title":"J Mark Access Health Policy"},{"issue":"1","key":"10.1016\/j.ejca.2023.03.041_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40258-019-00517-z","article-title":"Price models for multi-indication drugs: a systematic review","volume":"18","author":"Campillo-Artero","year":"2020","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"10.1016\/j.ejca.2023.03.041_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1017\/S0266462315000446","article-title":"Monitoring registries at Italian Medicines Agency: fostering access, guaranteeing sustainability","volume":"31","author":"Montilla","year":"2015","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.ejca.2023.03.041_bib22","unstructured":"Italian Ministry of Health, Misure volte a facilitare e sostenere la realizzazione degli studi clinici di medicinali senza scopo di lucro e degli studi osservazionali e a disciplinare la cessione di dati e risultati di sperimentazioni senza scopo di lucro a fini registrativi, ai sensi dell'art. 1, comma 1, lettera c), del decreto legislativo 14 maggio 2019, n. 52. (22A01189). 2021: GU Serie Generale n.42 del 19-02-2022."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:09Z","timestamp":1760733669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923001788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":22,"alternative-id":["S0959804923001788"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.041","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do more targets allow more cancer treatments, or not?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}